Pfizer, Repligen unite to develop spinal muscular atrophy drugs

Pfizer and Repligen will develop the latter's spinal muscular atrophy program including experimental SMA drug RG3039 as part of a licensing deal. RG3039, which was licensed from patient advocacy group Families of SMA, holds orphan-drug status in the U.S. and Europe as well as fast-track designation in the U.S. Repligen will receive $5 million upfront and as much as $65 million in milestone fees plus royalties.

View Full Article in:

Genetic Engineering & Biotechnology News · Bloomberg Businessweek

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Vice-President of Technology and Regulatory Affairs
AdvaMed
Washington DC, DC
Sr Product Manager Global Marketing (US/DA/00/0085/SL) - 14000009V3
Abbott
Chicago, IL
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Director of Medicare Products
Bluegrass Family Health
Lexington, KY
Vice President, Information Technology
HealthPartners
MN